MacroGenics Inc
$ 3.96
-1.25%
12 Jun - close price
- Market Cap 251,710,000 USD
- Current Price $ 3.96
- High / Low $ 4.12 / 3.93
- Stock P/E N/A
- Book Value 0.33
- EPS -1.11
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -1.40 %
- 52 Week High 4.64
- 52 Week Low 1.19
About
MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States. The company is headquartered in Rockville, Maryland.
Analyst Target Price
$6.75
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-09 | 2025-11-12 | 2025-08-14 | 2025-05-13 | 2025-03-20 | 2024-11-05 | 2024-08-06 | 2024-05-09 | 2024-03-07 | 2023-11-06 | 2023-08-09 |
| Reported EPS | -0.58 | -0.22 | 0.27 | -0.57 | -0.65 | -0.818 | 0.9 | -0.89 | -0.84 | -0.75 | 0.28 | -0.69 |
| Estimated EPS | -0.5475 | -0.2696 | -0.41 | -0.46 | -0.69 | -0.59 | 0.21 | -0.59 | -0.64 | -0.15 | -0.1 | -0.52 |
| Surprise | -0.0325 | 0.0496 | 0.68 | -0.11 | 0.04 | -0.228 | 0.69 | -0.3 | -0.2 | -0.6 | 0.38 | -0.17 |
| Surprise Percentage | -5.9361% | 18.3976% | 165.8537% | -23.913% | 5.7971% | -38.6441% | 328.5714% | -50.8475% | -31.25% | -400% | 380% | -32.6923% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MGNX
2026-06-12 17:08:43
MacroGenics Inc. (MGNX) stock valuation is under renewed scrutiny after a recent biotech rally cooled down. Investors are focusing on fundamental metrics like market capitalization, cash position, burn rate, and pipeline risk given the company's status as a pre-commercial, clinical-stage oncology specialist. The article highlights how MacroGenics' valuation, unlike that of established pharmaceutical companies, is heavily influenced by clinical milestones, partnership deals, and the broader biotech funding environment, rather than traditional earnings.
2026-06-05 21:09:55
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly reported shared voting and dispositive power over 3,435,504 shares of MacroGenics (MGNX) common stock, representing 5.4% of the class. This disclosure was made via a Schedule 13G filing, indicating a passive investment rather than an intent to control the company. The filing notes a "Filed date anchor" of June 1, 2026, and includes a Joint Filing Agreement dated June 4, 2026.
2026-06-04 16:39:03
This article provides a detailed stock analysis of MacroGenics (MGNX), a clinical-stage biopharmaceutical company. It covers the company's valuation, future growth prospects, past performance, financial health, and dividend policy, along with analyst ratings and recent news. The analysis highlights the company's highly volatile share price, current unprofitability, and reliance on successful clinical trials for future growth, while noting recent positive analyst sentiment and revenue estimate increases.
2026-05-29 22:39:34
MacroGenics has expanded its royalty agreement with Sagard, centered on its oncology drug ZYNYZ (retifanlimab-dlwr), securing an additional $60 million upfront. This new agreement builds upon their existing 2023 collaboration for multiple oncology assets. The funding will further support the commercialization of ZYNYZ and MacroGenics' broader drug development pipeline.
2026-05-29 09:39:06
MacroGenics Inc. (MGNX) shares experienced a slight decline on May 28, 2026, after a period of significant year-to-date gains, reflecting broader profit-taking and risk rotation in the U.S. biotech sector. Despite the pullback, the stock trades below the average twelve-month price target of USD 5.50 set by Wall Street analysts, who maintain a "hold" rating. The valuation debate for this development-stage biotech company centers on pipeline execution, partnership economics, and clinical funding risks.
2026-05-21 09:42:12
MACROGENICS director Federica F. O'Brien reported a recent equity compensation and option exercise. On May 18, 2026, 3,750 restricted stock units vested, converting into common shares, and on May 19, 2026, she was granted an additional 3,750 RSUs and a 22,000-share stock option with an exercise price of $4.52, expiring in 2036. Following these transactions, O'Brien directly holds 14,750 common shares.
